Form 4: Savara Inc. CFO David Lowrance Reports Stock Transactions

Savara Inc.'s Chief Financial Officer, David Lowrance, reported a series of stock transactions including acquisitions, disposals, and option grants.

Summary

• David Lowrance, the Chief Financial Officer of Savara Inc., reported several transactions involving the company's stock.
• On December 12, 2024, Mr. Lowrance acquired 100,000 shares of common stock through restricted stock units (RSUs) that will vest on December 12, 2026.
• Also on December 12, 2024, he was granted an option to purchase 300,000 shares of common stock at an exercise price of $3.35, vesting quarterly over four years.
• On December 13, 2024, Mr. Lowrance gifted 12,000 shares to The McCallie School.
• On the same day, 24,350 shares were withheld by the company to cover tax liabilities from vesting RSUs.
• On December 16, 2024, Mr. Lowrance sold 25,000 shares at a weighted average price of $3.3311, with prices ranging from $3.29 to $3.36, to cover tax liabilities.
• Following these transactions, Mr. Lowrance directly owns 381,005 shares of Savara Inc. common stock and options for 300,000 shares.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, with no significant positive or negative implications. The sale of shares is for tax purposes, which is a common practice.

Positives

• The grant of 100,000 restricted stock units and 300,000 stock options to the CFO indicates a continued alignment of interests with the company's long-term success.
• The vesting schedule of the options and RSUs encourages long-term commitment from the CFO.

Negatives

• The sale of 25,000 shares by the CFO, while for tax purposes, could be perceived negatively by some investors.

Risks

• The sale of shares by an executive, even for tax purposes, could potentially create short-term market volatility.
• The vesting of a large number of shares in the future could potentially lead to further sales by the executive.

Future Outlook

The restricted stock units vest in full on December 12, 2026, and the stock options vest quarterly over four years, both subject to continued service with the company.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the trading activities of key executives.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotech industry.
• The sale of shares to cover tax liabilities is a common practice among executives who receive equity compensation.
• Companies like Amgen, Gilead, and Biogen also regularly report similar insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by the CFO.
• The vesting of RSUs and options aligns the CFO's interests with the long-term performance of the company.

Key Dates

Keywords

Savara Inc, David Lowrance, stock transactions, Form 4, restricted stock units, stock options, insider trading, executive compensation, share sales, tax liabilities